Cargando…
The dynamics of HER2 status in esophageal adenocarcinoma
Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on ar...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003553/ https://www.ncbi.nlm.nih.gov/pubmed/29928485 http://dx.doi.org/10.18632/oncotarget.25507 |
_version_ | 1783332378477854720 |
---|---|
author | Creemers, Aafke Ebbing, Eva A. Hooijer, Gerrit K.J. Stap, Lisanne Jibodh-Mulder, Rajni A. Gisbertz, Susanne S. van Berge Henegouwen, Mark I. van Montfoort, Maurits L. Hulshof, Maarten C.C.M. Krishnadath, Kausilia K. van Oijen, Martijn G.H. Bijlsma, Maarten F. Meijer, Sybren L. van Laarhoven, Hanneke W.M. |
author_facet | Creemers, Aafke Ebbing, Eva A. Hooijer, Gerrit K.J. Stap, Lisanne Jibodh-Mulder, Rajni A. Gisbertz, Susanne S. van Berge Henegouwen, Mark I. van Montfoort, Maurits L. Hulshof, Maarten C.C.M. Krishnadath, Kausilia K. van Oijen, Martijn G.H. Bijlsma, Maarten F. Meijer, Sybren L. van Laarhoven, Hanneke W.M. |
author_sort | Creemers, Aafke |
collection | PubMed |
description | Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on archived material of the primary tumor. However, this status may change over the course of treatment or disease progression. The aim of this study was to assess the dynamics of HER2 status in esophageal adenocarcinoma (EAC) in patients with resectable and recurrent disease, and to determine the associations of these changes with clinical outcome. Discordance, defined as any change in HER2 status between matched biopsy and post-neoadjuvant chemoradiation therapy resection specimen (N = 170), or between matched resection specimen and recurrence of patients not eligible for curative treatment (N = 61), was determined using the standardized HER2 status scoring system. Clinically relevant positive discordance was defined as a change to HER2 positive status, as this would imply eligibility for HER2-targeted therapy. A difference in HER2 status between biopsy and resection specimen and resection specimen and metachronous recurrence was observed in 2.1% (n = 3) and 3.3% (n = 2) of the paired cases, respectively. Clinically relevant discordance was detected in 1.4% (n = 2) of the resectable patients and 1.6% (n = 1) of the patients with recurrent disease. Patients with HER2-positive status tumors before start of neoadjuvant treatment showed better overall survival, but not statistically significant. No association between HER2 status discordance and survival was found. Clinically relevant HER2 status discordance was observed and in order to prevent under-treatment of patients, the assessment of HER2 status in the metastatic setting should preferably be performed on the most recently developed lesions if the previous HER2 assessment on archival material of the primary tumor was negative. |
format | Online Article Text |
id | pubmed-6003553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-60035532018-06-20 The dynamics of HER2 status in esophageal adenocarcinoma Creemers, Aafke Ebbing, Eva A. Hooijer, Gerrit K.J. Stap, Lisanne Jibodh-Mulder, Rajni A. Gisbertz, Susanne S. van Berge Henegouwen, Mark I. van Montfoort, Maurits L. Hulshof, Maarten C.C.M. Krishnadath, Kausilia K. van Oijen, Martijn G.H. Bijlsma, Maarten F. Meijer, Sybren L. van Laarhoven, Hanneke W.M. Oncotarget Research Paper Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined on archived material of the primary tumor. However, this status may change over the course of treatment or disease progression. The aim of this study was to assess the dynamics of HER2 status in esophageal adenocarcinoma (EAC) in patients with resectable and recurrent disease, and to determine the associations of these changes with clinical outcome. Discordance, defined as any change in HER2 status between matched biopsy and post-neoadjuvant chemoradiation therapy resection specimen (N = 170), or between matched resection specimen and recurrence of patients not eligible for curative treatment (N = 61), was determined using the standardized HER2 status scoring system. Clinically relevant positive discordance was defined as a change to HER2 positive status, as this would imply eligibility for HER2-targeted therapy. A difference in HER2 status between biopsy and resection specimen and resection specimen and metachronous recurrence was observed in 2.1% (n = 3) and 3.3% (n = 2) of the paired cases, respectively. Clinically relevant discordance was detected in 1.4% (n = 2) of the resectable patients and 1.6% (n = 1) of the patients with recurrent disease. Patients with HER2-positive status tumors before start of neoadjuvant treatment showed better overall survival, but not statistically significant. No association between HER2 status discordance and survival was found. Clinically relevant HER2 status discordance was observed and in order to prevent under-treatment of patients, the assessment of HER2 status in the metastatic setting should preferably be performed on the most recently developed lesions if the previous HER2 assessment on archival material of the primary tumor was negative. Impact Journals LLC 2018-06-01 /pmc/articles/PMC6003553/ /pubmed/29928485 http://dx.doi.org/10.18632/oncotarget.25507 Text en Copyright: © 2018 Creemers et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Creemers, Aafke Ebbing, Eva A. Hooijer, Gerrit K.J. Stap, Lisanne Jibodh-Mulder, Rajni A. Gisbertz, Susanne S. van Berge Henegouwen, Mark I. van Montfoort, Maurits L. Hulshof, Maarten C.C.M. Krishnadath, Kausilia K. van Oijen, Martijn G.H. Bijlsma, Maarten F. Meijer, Sybren L. van Laarhoven, Hanneke W.M. The dynamics of HER2 status in esophageal adenocarcinoma |
title | The dynamics of HER2 status in esophageal adenocarcinoma |
title_full | The dynamics of HER2 status in esophageal adenocarcinoma |
title_fullStr | The dynamics of HER2 status in esophageal adenocarcinoma |
title_full_unstemmed | The dynamics of HER2 status in esophageal adenocarcinoma |
title_short | The dynamics of HER2 status in esophageal adenocarcinoma |
title_sort | dynamics of her2 status in esophageal adenocarcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003553/ https://www.ncbi.nlm.nih.gov/pubmed/29928485 http://dx.doi.org/10.18632/oncotarget.25507 |
work_keys_str_mv | AT creemersaafke thedynamicsofher2statusinesophagealadenocarcinoma AT ebbingevaa thedynamicsofher2statusinesophagealadenocarcinoma AT hooijergerritkj thedynamicsofher2statusinesophagealadenocarcinoma AT staplisanne thedynamicsofher2statusinesophagealadenocarcinoma AT jibodhmulderrajnia thedynamicsofher2statusinesophagealadenocarcinoma AT gisbertzsusannes thedynamicsofher2statusinesophagealadenocarcinoma AT vanbergehenegouwenmarki thedynamicsofher2statusinesophagealadenocarcinoma AT vanmontfoortmauritsl thedynamicsofher2statusinesophagealadenocarcinoma AT hulshofmaartenccm thedynamicsofher2statusinesophagealadenocarcinoma AT krishnadathkausiliak thedynamicsofher2statusinesophagealadenocarcinoma AT vanoijenmartijngh thedynamicsofher2statusinesophagealadenocarcinoma AT bijlsmamaartenf thedynamicsofher2statusinesophagealadenocarcinoma AT meijersybrenl thedynamicsofher2statusinesophagealadenocarcinoma AT vanlaarhovenhannekewm thedynamicsofher2statusinesophagealadenocarcinoma AT creemersaafke dynamicsofher2statusinesophagealadenocarcinoma AT ebbingevaa dynamicsofher2statusinesophagealadenocarcinoma AT hooijergerritkj dynamicsofher2statusinesophagealadenocarcinoma AT staplisanne dynamicsofher2statusinesophagealadenocarcinoma AT jibodhmulderrajnia dynamicsofher2statusinesophagealadenocarcinoma AT gisbertzsusannes dynamicsofher2statusinesophagealadenocarcinoma AT vanbergehenegouwenmarki dynamicsofher2statusinesophagealadenocarcinoma AT vanmontfoortmauritsl dynamicsofher2statusinesophagealadenocarcinoma AT hulshofmaartenccm dynamicsofher2statusinesophagealadenocarcinoma AT krishnadathkausiliak dynamicsofher2statusinesophagealadenocarcinoma AT vanoijenmartijngh dynamicsofher2statusinesophagealadenocarcinoma AT bijlsmamaartenf dynamicsofher2statusinesophagealadenocarcinoma AT meijersybrenl dynamicsofher2statusinesophagealadenocarcinoma AT vanlaarhovenhannekewm dynamicsofher2statusinesophagealadenocarcinoma |